The Servier Group and Symphogen

Symphogen was founded in 2000 – and in 2020 Symphogen became a member of Servier Pharmaceutical as the R&D Antibody Center of Excellence. The Servier Group is a global pharmaceutical company governed by a non-profit foundation, with headquarters in Paris, France.

Please visit the Servier newsroom for corporate news, press releases, and medical and corporate publications, including annual reports and CSR reports.

With €4.9 billion consolidated sales revenue 2022 achieved in 150 countries, Servier employ 21,400 people worldwide. A leader in cardiology, the ambition of the Servier Group is to become a recognized and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology and immuno-inflammatory, and neurodegenerative diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.